UPDATE: Stifel Nicolaus Reiterates Buy Rating, Lowers PT on Sabra Health Care REIT Following Quarter FFO Report

In a report published Thursday, Stifel Nicolaus analyst Robert Mains reiterated a Buy rating on Sabra Health Care REIT SBRA, but lowered the price target from $32.00 to $30.. In the report, Stifel Nicolaus noted, “Sabra Health Care REIT reported second quarter normalized FFO of $0.42 (0.41 as reported by the company) and FAD of $0.41. These figures compare to our estimates of $0.44 and $0.40, respectively, so are in line with our expectations. The quarter's largest nonrecurring item was a $10.5 million ($10.0 million cash) loss on debt extinguishment, including additional interest. Sabra incurred $229,000 in transaction costs that we exclude from normalized FFO but the company does not.” Sabra Health Care REIT closed on Wednesday at $26.30.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetAnalyst RatingsRobert MainsStifel Nicolaus
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!